共 5 条
[1]
Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre; open-label; phase 1b trial[J] James L Gulley;Arun Rajan;David R Spigel;Nicholas Iannotti;Jason Chandler;Deborah J L Wong;Joseph Leach;W Jeff Edenfield;Ding Wang;Hans Juergen Grote;Anja von Heydebreck;Kevin Chin;Jean-Marie Cuillerot;Karen Kelly The Lancet Oncology 2017,
[2]
Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma[J] Tatsuya Yoshida;Genichiro Ishii;Koichi Goto;Kiyotaka Yoh;Seiji Niho;Shigeki Umemura;Shingo Matsumoto;Hironobu Ohmatsu;Kanji Nagai;Yuichiro Ohe;Atsushi Ochiai Journal of Cancer Research and Clinical Oncology 2013,
[3]
What Lies Within: Novel Strategies in Immunotherapy for Non-Small Cell Lung Cancer[J] Patrick M. Forde;Kim A. Reiss;Amer M. Zeidan;Julie R. Brahmer The Oncologist 2013,
[4]
Targeted therapy for non-small-cell lung cancer: past; present and future[J] Forde;Ettinger Expert Review of Anticancer Therapy 2013,
[5]
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre; open-label; randomised phase 3 trial[J] Lancet Oncology 2012,